DMT Shows Promise in Rapidly Reducing Depressive Symptoms

A recent clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation and the need for larger, long-term studies.

What is DMT and How Does it Work?

Dimethyltryptamine (DMT) is a naturally occurring tryptamine that acts as a serotonin 5-hydroxytryptamine receptor 2A agonist. Recent research has explored its potential for treating mood disorders. Unlike other psychedelics, DMT has a short half-life and brief psychoactive duration, potentially improving feasibility and scalability of treatment sessions.

Phase IIa Trial Design and Results

Researchers evaluated the safety and effectiveness of intravenous DMT infusion in adults with major depressive disorder (MDD) in a two-stage, randomized, placebo-controlled phase IIa trial. The study included participants aged 18 years or older with moderate-to-severe MDD who had previously experienced unsuccessful treatment attempts.

Participants received up to two intravenous doses of DMT or placebo, accompanied by psychotherapeutic support, including preparatory sessions, monitored dosing, and post-session psychological integration. The dose administered was 21.5 mg DMT fumarate infused intravenously over 10 minutes.

Key Findings

• The mean change in Montgomery–Åsberg Depression Rating Scale (MADRS) score from baseline to two weeks after the first dose was significantly greater in DMT recipients compared to placebo recipients.
• Reductions in MADRS scores were also significant at one week after dosing.
• Most clinical improvements occurred within two weeks of the first DMT dose.
• At one week, response rates (greater than 50% decrease in MADRS score) were 6% in the placebo group and 44% in the DMT group, with remission rates (MADRS score ≤ 10) of 13% and 44%, respectively.
• At two weeks, response rates were 12% in the placebo group and 35% in the DMT group, with remission rates of 12% and 29%, respectively.

Researchers noted that the pronounced subjective effects of DMT may have led to functional unblinding in the study.

Safety and Tolerability

The treatment was generally well-tolerated. Most participants (approximately three-fourths) reported treatment-emergent adverse events (TEAEs), which were mild in 15 participants and moderate in 10. Common TEAEs included injection site pain, anxiety, insomnia, headache, and restlessness.

No serious adverse events or deaths occurred during the trial. Transient increases in heart rate and blood pressure were observed immediately after DMT infusion, but no meaningful changes in suicidal ideation were reported. Clinical evaluations, including ECGs and laboratory tests, revealed no significant abnormalities.

Future Directions

This phase IIa study suggests that a single 21.5 mg dose of DMT, administered with psychological support, can lead to rapid and significant reductions in depressive symptoms that persist for up to three months in adults with MDD. However, these findings are based on a small, carefully screened study population.

Larger, longer studies are needed to further evaluate the safety, efficacy, durability of response, and cost-effectiveness of DMT for the treatment of MDD, including comparisons with current therapies. Further research is also needed to understand the neuropsychological mechanisms underlying these effects.